Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Multiple sclerosis

Natalizumab to fingolimod—the washout whitewash

Nature Reviews Neurology volume 10, pages 311–313 (2014)Cite this article

Subjects

A recent multicentre study has assessed the risk of relapse in patients with multiple sclerosis who switched from natalizumab to fingolimod treatment. Despite such efforts, no effective exit strategy from natalizumab treatment has yet been demonstrated for these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biological effects of natalizumab and fingolimod.

References

  1. Cohen, M. et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 71, 436–441 (2014).

    Article  Google Scholar 

  2. O'Connor, P. W. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76, 1858–1865 (2011).

    Article  CAS  Google Scholar 

  3. Jokubaitis, V. G. et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology 82, 1204–1211 (2014).

    Article  CAS  Google Scholar 

  4. Kappos, L. et al. Disease control and safety in relapsing–remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). Mult. Scler. 19 (Suppl. 1), 50 (2013).

    Google Scholar 

  5. Bloomgren, G. et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 366, 1870–1880 (2012).

    Article  CAS  Google Scholar 

  6. Krumbholz, M., Meinl, I., Kümpfel, T., Hohlfeld, R. & Meinl, E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 71, 1350–1354 (2008).

    Article  CAS  Google Scholar 

  7. Kivisakk, P. et al. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72, 1922–1930 (2009).

    Article  CAS  Google Scholar 

  8. Fine, A. J., Sorbello, A., Kortepeter, C. & Scarazzini, L. Progressive multifocal leukoencephalopathy after natalizumab discontinuation. Ann. Neurol. 75, 108–115 (2014).

    Article  CAS  Google Scholar 

  9. Stüve, O. et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72, 396–401 (2009).

    Article  Google Scholar 

  10. Brinkmann, V. et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277, 21453–21457 (2002).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Clinical Neuroimmunology and Neurochemistry, Hannover Medical School, Hannover, Germany

    Martin Stangel

  2. Neurology Section, VA North Texas Health Care System, Medical Service Dallas, VA Medical Centre, 4500 South Lancaster Road, Dallas, 75216, TX, USA

    Olaf Stüve

Authors
  1. Martin Stangel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olaf Stüve
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Olaf Stüve.

Ethics declarations

Competing interests

M.S. has received honoraria or consultancy payments from Bayer Healthcare, Biogen Idec, Baxter, CSL Behring, Grifols, Merck-Serono, Novartis, Sanofi-Aventis, and Teva. His institution has received research support from Bayer Healthcare, Biogen Idec, Merck-Serono, Novartis, and Teva. O.S. declares no competing interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stangel, M., Stüve, O. Natalizumab to fingolimod—the washout whitewash. Nat Rev Neurol 10, 311–313 (2014). https://doi.org/10.1038/nrneurol.2014.82

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneurol.2014.82

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing